XtalPi Launches Kodexia siRNA Discovery Platform
XtalPi announced in a press release the launch of Kodexia, a siRNA discovery platform combining generative AI, first principles biological modeling, and automated experiments. The platform covers sequence design, chemical modification, experimental validation, delivery design, and intellectual property analysis.
Kodexia connects computational models with automated laboratories that conduct more than 500 in vitro and 30 in vivo experiments each week. XtalPi said internal tests showed nearly three times greater design efficiency than conventional processes, while more than 50% of first round designs across several programs produced stronger in vivo activity than positive controls.
The lead program targets immunoglobulin A nephropathy and produced nonhuman primate efficacy data within seven months. XtalPi said it showed greater activity and durability than a clinical stage reference molecule targeting the same target.
Kodexia currently supports six internal programs covering metabolic, renal, respiratory, and central nervous system diseases. The platform also designs dual target siRNA molecules and delivery systems using antibody, peptide, and small molecule conjugates for tissues including the kidney, spleen, and adipose tissue.
We hope you enjoyed this article
Consider subscribing to one of our newsletters like Life AI Weekly or Daily AI Brief.
Also, consider following us on social media:
More from Life Sciences
Nov 22 MedInTech raises $25.7 million for AI robotic endoscopes Nov 21 ModuleMD shows AI documentation, front-desk agents and skin-test measurement for allergy EHR Nov 21 Chelsea and Westminster Hospital launches multilingual AI avatar platform for lung cancer patients Nov 21 ChatGPT Health reaches Android, desktop and dots; health chats now follow the training setting Nov 20 OpenAI launches MedChemBench to test AI models on medicinal chemistry reasoningLife AI Weekly
Weekly coverage of AI applications in healthcare, drug development, biotechnology research, and genomics breakthroughs.
Industry analysis
2025 Global Business Services Agenda: Gen AI Takes Center Stage
This industry analysis by The Hackett Group explores the transformative impact of generative artificial intelligence (Gen AI) on global business services (GBS) in 2025. The study highlights the shift from exploration to acceleration of Gen AI initiatives, with 89% of executives advancing these projects to improve customer satisfaction, innovate products, and reduce costs. The report also discusses the challenges and strategies for successful Gen AI adoption, emphasizing the need for a technology-enabled operating model and the importance of reskilling the workforce.
Read moreYou may also like
Isomorphic Labs and MSD team up to design cancer drugs with AI
Flagship Pioneering Merges Three Biotech Platforms Into Etcelera
Adsilico Raises £10 Million for Virtual Medical Device Testing
Isomorphic Labs raises $5 billion Series C for AI drug design
Switchpoint Bio raises $5.3 million for AI epigenomics platform
Daily AI Brief: the AI news that matters, in your inbox.